(R)-(+/-)-4-[4'-(1-pyrrolidin-1-ylethyl)-biphenyl-4-yl]-piperidine | 868396-83-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (R)-(+/-)-4-[4'-(1-pyrrolidin-1-ylethyl)-biphenyl-4-yl]-piperidine
• 英文别名: (R)-4-[4'-(1-Pyrrolidin-1-ylethyl)-biphenyl-4-yl]-piperidine；4-[4-[4-[(1R)-1-pyrrolidin-1-ylethyl]phenyl]phenyl]piperidine
• CAS: 868396-83-2
• 化学式: C₂₃H₃₀N₂
• 分子量: 334.505
• InChiKey: XFVYWNHZMVXXLN-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-(+/-)-4-[4'-(1-pyrrolidin-1-ylethyl)-biphenyl-4-yl]-piperidine 、 甲基磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-Methanesulfonyl-4-[4'-(1-pyrrolidin-1-ylethyl)-biphenyl-4-yl]-piperidine
  参考文献：
  名称：

  Histamine-3 receptor antagonists

  摘要：

  本发明涉及根据本文所定义的式I的化合物，或其药学上可接受的盐；含有式I化合物的药物组合物；一种治疗可能通过拮抗组胺H3受体而治疗的疾病或症状的方法，该方法包括向需要这种治疗的哺乳动物施用上述式I化合物；以及一种治疗选自抑郁症、情绪障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、精神障碍、睡眠障碍、肥胖、眩晕、癫痫、晕动病、呼吸道疾病、过敏、过敏引起的气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道高低蠕动和酸性分泌的疾病或症状的方法，该方法包括向需要这种治疗的哺乳动物施用上述式I化合物。

  公开号：

  US20050245543A1
• 作为产物：
  描述：

  (R)-(+/-)-4-[4'-(1-pyrrolidin-1-ylethyl)-biphenyl-4-yl]-pyridine 在 platinum(II) oxide 氢气 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 (R)-(+/-)-4-[4'-(1-pyrrolidin-1-ylethyl)-biphenyl-4-yl]-piperidine
  参考文献：
  名称：

  Histamine-3 receptor antagonists

  摘要：

  本发明涉及根据本文所定义的式I的化合物，或其药学上可接受的盐；含有式I化合物的药物组合物；一种治疗可能通过拮抗组胺H3受体而治疗的疾病或症状的方法，该方法包括向需要这种治疗的哺乳动物施用上述式I化合物；以及一种治疗选自抑郁症、情绪障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、精神障碍、睡眠障碍、肥胖、眩晕、癫痫、晕动病、呼吸道疾病、过敏、过敏引起的气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道高低蠕动和酸性分泌的疾病或症状的方法，该方法包括向需要这种治疗的哺乳动物施用上述式I化合物。

  公开号：

  US20050245543A1

文献信息

• HISTAMINE-3 RECEPTOR ANTAGONISTS
  申请人：Pfizer Products Incorporated

  公开号：EP1756058A1

  公开（公告）日：2007-02-28
• [EN] HISTAMINE-3 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS DE L'HISTAMINE H3
  申请人：PFIZER PROD INC

  公开号：WO2005105744A1

  公开（公告）日：2005-11-10

  This invention is directed to a compound of the formula (I) as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy- induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro- intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.
• Histamine-3 receptor antagonists
  申请人：Howard R. Harry

  公开号：US20050245543A1

  公开（公告）日：2005-11-03

  This invention is directed to a compound of the formula I as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

  本发明涉及根据本文所定义的式I的化合物，或其药学上可接受的盐；含有式I化合物的药物组合物；一种治疗可能通过拮抗组胺H3受体而治疗的疾病或症状的方法，该方法包括向需要这种治疗的哺乳动物施用上述式I化合物；以及一种治疗选自抑郁症、情绪障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、精神障碍、睡眠障碍、肥胖、眩晕、癫痫、晕动病、呼吸道疾病、过敏、过敏引起的气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道高低蠕动和酸性分泌的疾病或症状的方法，该方法包括向需要这种治疗的哺乳动物施用上述式I化合物。